Table 4. Multivariable analysis of the association between consolidation chemotherapy (CCT) or neoadjuvant chemoradiotherapy (nCRT) and pathological complete response (pCR).
| Crude OR (95% CI) | Adjusted OR (95% CI) | P value | |
|---|---|---|---|
| Neoadjuvant therapy | |||
| CRT | Ref. | Ref. | |
| CCRT | 4.6 [1.3–16.6] | 4.91 [1.01–23.79] | 0.048 |
| Sex | |||
| Male | Ref. | Ref. | |
| Female | 0.47 [0.18–1.25] | 2.85 [0.93–8.75] | 0.07 |
| CEA | |||
| <5 (ng/ml) | Ref. | Ref. | |
| >5 (ng/ml) | 0.94 [0.35–2.52] | 0.88 [0.28–2.67] | 0.82 |
| Clinical T-stage | |||
| cT3 | Ref. | Ref. | |
| cT4 | 1.21 [0.44–3.31] | 1.38 [0.44–4.33] | 0.58 |
| Clinical N-stage | |||
| cN0 | Ref. | Ref. | |
| cN1 | 0.54 [0.17–1.75] | 0.49 [0.12–2.01] | 0.32 |
| cN2 | 0.39 [0.08–1.84] | 0.23 [0.38–1.42] | 0.11 |
| Time interval | |||
| <6 weeks | Ref. | Ref. | |
| 6–10 weeks | 3.79 [0.79–17.97] | 1.97 [0.30–12.9] | 0.47 |
| >10 weeks | 5.72 [1.07–30.77] | 4.41 [0.58–33.2] | 0.14 |
Note:
CEA, carcinoembryonic antigen; OR, odds ratio.